FOXA1 expression has been shown to positively associate with ER+ breast cancer [47], and its overexpression has been correlated with endocrine resistance via its capacity to trigger oncogenic gene signatures and pro-resistance proteomic profiles [65]. Here, FOXA1 is linked to breast carcinoma.